Form 4: Artiva Biotherapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 9, 2026.
Summary
- Grant/award: acquired 40,000 Common Stock on September 9, 2026; holds 323,084 after (Direct).
- Grant/award: acquired 120,000 Employee Stock Option (Right to Buy) on September 9, 2026; holds 120,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Christopher Horan — Officer (Chief Tech Operations Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Grant/award | Common Stock | 40,000 | — | — | 323,084 |
| 2026-09-09 | Grant/award | Employee Stock Option (Right to Buy) | 120,000 | — | — | 120,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Grant/award (40,000 shares) |
| 2026-09-09 | Grant/award (120,000 shares) |
Keywords
insider transaction, Form 4, ARTV, Artiva Biotherapeutics, Inc., neutral, Christopher Horan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.